PTCT

56.3703.35%
EP

Eric Pauwels

Chief Business Officer

Mr. Eric Pauwels has been Chief Business Officer at PTC Therapeutics, Inc. since April 16, 2020 and served as its Senior Vice President and General Manager of Commercial Operations, Americas since April 2015. Mr. Pauwels served as the President of NPS Pharma International at NPS Pharmaceuticals, Inc. since March 2014 and served as its Senior Vice President since September 26, 2011. Mr. Pauwels served as Chief Commercial Officer of NPS Pharmaceuticals, Inc. from September 26, 2011 to March 2014. He served as Senior Vice President of Global Commercial Operations at Shire Human Genetic Therapies Inc. from April 13, 2005 to 2010. He joined PTC Therapeutics, Inc in March 2015. Mr. Pauwels has extensive global healthcare experience from several top-tier US and global pharmaceutical companies. Mr. Pauwels also held global marketing and general management functions in the US, Europe and China with Shire, Bayer, Fournier and J&J. Mr. Pauwels served as Chief Marketing Officer and Senior Vice President of Accuray Incorporated since January 17, 2011. Mr. Pauwels was responsible for Shire Human Genetic Therapies's worldwide commercialization initiatives, including the potential launch of iduronate-2-sulfatase (I2S) for Hunter syndrome and ongoing marketing efforts for Replagal (TM), Shire Human Genetic Therapies Inc.'s enzyme replacement therapy for Fabry disease. Mr. Pauwels joined Shire Human Genetic Therapies from Bayer Healthcare Pharmaceuticals where he managed the global commercialization for LEVITRA(R) for erectile dysfunction in his role as Vice President Global Strategic Marketing, Men's Health. He served as Vice President Global Strategic Marketing of Cardiovascular of Bayer and held several positions of increasing responsibility in sales and marketing at Laboratories Fournier for more than. Mr. Pauwels has also held marketing and sales positions at Janssen Pharmaceutica Products and McNeil Pharmaceuticals where he managed several product launches, including RISPERDAL(R) for psychotic disorders. He played a key leadership role in building commercial capabilities in an early stage biotech company at Shire Human Genetic Therapies Inc. and leading Shire's worldwide commercial business for its Human Genetic Disease biotech business unit where he served as Senior Vice President and Chief Commercial Officer. He has extensive alliance management experience. Mr. Pauwels received a B.Sc. in Business Administration and Management from California State Polytechnic University, Pomona in 1986.

Positions